STOCK TITAN
  1. Home
  2. Sec-filings
  3. ASMB
  4. [8-K] Assembly Biosciences, Inc Reports Material Event

Assembly Biosciences unveils potent ABI-5366 efficacy, moves toward Phase 2

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Assembly Biosciences (ASMB) filed an 8-K reporting interim Phase 1b results for its long-acting HSV helicase-primase inhibitor ABI-5366.

The 350 mg once-weekly oral dose achieved a 94% reduction in HSV-2 viral shedding versus placebo (p<0.01) over 29 days, exceeding the study’s 80-85% target. Secondary endpoints also improved: 94% lower genital-lesion rate and 98% reduction in high-viral-load samples (p<0.05). The drug was well-tolerated at doses up to 350 mg weekly, and its pharmacokinetic profile supports both once-weekly and potential once-monthly dosing.

With these data, Assembly plans to move directly into Phase 2 preparations while finishing the Phase 1b trial’s monthly-dosing cohort. Chronic toxicology studies are complete and expected to support longer-term dosing in Phase 2.

Positive

  • 94% reduction in HSV-2 shedding versus placebo, surpassing the 80-85% target
  • 94% decrease in genital-lesion rate compared to placebo
  • 98% reduction in high viral-load samples (p<0.05)
  • Well-tolerated at oral doses up to 350 mg weekly
  • Data support once-weekly and potential once-monthly dosing; company advancing to Phase 2

Negative

  • Results are interim Phase 1b; efficacy and safety must be confirmed in larger trials
  • No financial data provided on funding needs or cash runway, leaving dilution risk unaddressed

Insights

TL;DR: Potent Phase 1b efficacy and tolerability materially de-risk ABI-5366 and justify immediate Phase 2 start.

The 94% viral-shedding reduction comfortably beats management’s 80-85% benchmark, indicating a strong antiviral signal at a convenient weekly dose. Coupled with 94% fewer lesions and 98% fewer high-load samples, the dataset compares favorably with existing nucleoside therapies while potentially offering less frequent dosing. Safety appears clean, removing a key early-stage hurdle. Although confirmation in larger Phase 2 cohorts is required, these data meaningfully raise the probability of clinical success and strengthen ASMB’s HSV franchise.

TL;DR: Early but impressive efficacy boosts pipeline value; still years from revenue.

Investors should view the disclosure as positive because it converts pre-clinical promise into quantifiable human efficacy, likely attracting partner or financing interest. However, the asset remains in Phase 1b, meaning regulatory approval and cash flows are distant and dependent on Phase 2/3 success. The filing contains no financial guidance, so runway and dilution risk remain open questions. Near-term share price may react favorably to the headline efficacy, but volatility will persist until larger studies validate durability and safety.

Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Understanding 8-K Material Events →
false 0001426800 0001426800 2025-08-08 2025-08-08
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 8, 2025

 

 

Assembly Biosciences, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-35005   20-8729264

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Two Tower Place, 7th Floor,

South San Francisco, California

   94080
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (833) 509-4583

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001   ASMB   The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 7.01 Regulation FD Disclosure.

On August 8, 2025, Assembly Biosciences, Inc. (the “Company”) issued a press release announcing interim results from the Phase 1b portion of its ongoing Phase 1a/b clinical study evaluating ABI-5366, an investigational long-acting herpes simplex virus (“HSV”) helicase-primase inhibitor candidate for recurrent genital herpes (the “ABI-5366 Study”). A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01 Other Events.

The Company announced interim results from the ABI-5366 Study. For the powered antiviral endpoint, HSV type 2 (“HSV-2”) shedding rate, highly potent antiviral activity was observed with a 94% reduction compared to placebo (p<0.01) over the 29-day evaluation period in the cohort evaluating a 350 mg weekly dose. This reduction exceeds our target for the study of an 80%-85% reduction in the rate of HSV-2 shedding.

For a secondary clinical endpoint of genital lesion rate, a 94% reduction compared to placebo (p<0.01) was observed with the 350 mg weekly dose. The rate of samples with high viral load (i.e., >104 copies/mL HSV DNA), a potential surrogate for HSV-2 transmission and a secondary endpoint, was reduced by 98% compared to placebo (p<0.05) in this cohort.

ABI-5366 was observed to be well-tolerated at oral doses up to 350 mg weekly in participants seropositive for HSV-2 with recurrent genital herpes. The observed pharmacokinetic profile continues to support once-weekly dosing and the potential for once-monthly oral dosing regimens. With these data, the Company expects to move directly into Phase 2 clinical study preparation in parallel with completion of this Phase 1b study, which includes an ongoing cohort evaluating a monthly oral dosing regimen. The in-life portions of chronic toxicology studies of ABI-5366 are now complete and these studies are expected to support longer-term dosing in Phase 2.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

Number

   

Description

99.1    Press Release dated August 8, 2025.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

    Assembly Biosciences, Inc.
Date: August 8, 2025     By:  

/s/ John O. Gunderson

      John O. Gunderson
      VP, General Counsel and Corporate Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What did Assembly Biosciences (ASMB) disclose in the 8-K?

The company furnished interim Phase 1b data showing a 94% HSV-2 shedding reduction with ABI-5366 and plans to start Phase 2.

How much did ABI-5366 reduce HSV-2 shedding versus placebo?

The 350 mg weekly dose cut shedding by 94% over 29 days (p<0.01).

Was ABI-5366 well-tolerated in the study?

Yes. Oral doses up to 350 mg weekly were well-tolerated with a supportive pharmacokinetic profile.

What are the next development steps for ABI-5366?

Assembly will begin Phase 2 preparations while completing the current Phase 1b cohort that is evaluating monthly dosing.

Which secondary endpoints improved in the trial?

Genital-lesion rate fell 94% and high-viral-load samples dropped 98% compared to placebo.

On which exchange is ASMB listed?

ASMB trades on The Nasdaq Global Select Market.